Is Cencora (COR) overvalued or fairly valued?

MarketChacha shows Cencora's valuation in context — a trailing P/E of about 18.3, a forward P/E of about 17.3, a price-to-book of about 21.4 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

Does Cencora's reported profit turn into cash?

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash. MarketChacha computes this cash-conversion check (2.34×) from reported figures — education, not a rating.

What is Cencora's revenue?

Cencora reported revenue of $321.3B for FY2025, with net profit of $1.6B, per official filings.

What is the share price of Cencora (COR)?

Cencora last traded at $343.27 (+1.0% on the day), as of 10/20/2026 — a delayed quote shown for education, not investment advice.

Cencora

COR · NYSE · Healthcare · United States

Snapshot

TickerCOR

ExchangeNYSE

SectorHealthcare

IndustryMedical Distribution

CountryUnited States

Employees47,000

HeadquartersConshohocken, United States

Websitewww.cencora.com

Filings tracked25

About Cencora

Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company's U.S. Healthcare Solutions segment distributes generic and injectable pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; distributes plasma and other blood products, vaccines, and other specialty pharmaceutical products; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and other services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; sales force services to manufacturers; and offers other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. Its International Healthcare Solutions segment provides international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals; and offers specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was founded in 1871 and is headquartered in Conshohocken, Pennsylvania.

Who owns it

Insiders4.3%
Institutions95.7%
Public & other0.0%

1,872 institutional holders

Ownership breakdown from public market data.

Top holders

Blackrock Inc.9.54%
Vanguard Capital Management LLC6.49%
Vanguard Portfolio Management LLC5.04%
State Street Corporation4.86%
T. Rowe Price Investment Management, Inc.3.88%
Price (T.Rowe) Associates Inc3.74%
JPMORGAN CHASE & CO3.11%
Geode Capital Management, LLC2.86%

Largest institutional holders — last updated 6/30/2026.

Forensic scorecard

No major accounting red flags in the fundamentals we have — profit is backed by cash and returns look healthy.

Cash conversion2.34×

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash.

Net margin trend0.7% → 0.5%

Margin has held broadly steady over the period — stable profitability.

Return on equity103.1%

Latest ROE of 103.1% — capital is generating a healthy return.

Growth qualityrev 11% · PAT -6%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $89.9B · EPS 4.60

Est. earnings growth +12.8%

Next fiscal year

Rev $351.7B · EPS 19.75

Est. earnings growth +10.5%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Revenue (FY2025)

$321.3B

Net margin

0.5%

ROE

103.1%

Revenue CAGR (2y)

+10.7%

Profit CAGR (2y)

-5.6%

EPS (FY2025)

7.96

Net profit (FY2025)

$1.6B

Ask MarketChacha about COR

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$321.3B	$1.6B	7.96	0.5%	103.1%
FY2024	$294.0B	$1.5B	7.53	0.5%	233.6%
FY2023	$262.2B	$1.7B	8.53	0.7%	334.3%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q2	$84.8B	$763.5M	3.94	0.9%
2026Q1	$78.4B	$1.6B	8.40	2.1%
2025Q4	$85.9B	$559.6M	2.87	0.7%
2025Q2	$80.7B	$687.4M	3.52	0.9%
2025Q1	$75.5B	$717.9M	3.68	1.0%
2024Q4	$81.5B	$488.6M	2.50	0.6%
2024Q2	$74.2B	$483.5M	2.42	0.7%
2024Q1	$68.4B	$420.8M	2.09	0.6%
2023Q4	$72.3B	$601.5M	2.98	0.8%
2023Q2	$66.9B	$479.6M	2.35	0.7%
2023Q1	$63.5B	$435.4M	2.13	0.7%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

8-K — Executive/director change
SEC8/14/2026material
8-K — Reg FD disclosure
SEC8/12/2026material
10-Q filing
SEC8/5/2026
8-K — Material agreement, Material financial obligation, Exhibits
SEC8/5/2026material
8-K — Results of operations, Reg FD disclosure, Exhibits
SEC8/5/2026material
8-K — Executive/director change, Reg FD disclosure, Exhibits
SEC6/15/2026material
8-K — Executive/director change, Reg FD disclosure, Exhibits
SEC5/29/2026material
8-K — Results of operations, Reg FD disclosure, Exhibits
SEC5/6/2026material
10-Q filing
SEC5/6/2026
8-K — Reg FD disclosure, Exhibits
SEC3/23/2026material
8-K — Executive/director change, Reg FD disclosure, Exhibits
SEC3/17/2026material
8-K — Shareholder vote results
SEC3/6/2026material
8-K — Reg FD disclosure, Other events, Exhibits
SEC2/18/2026material
8-K — Material agreement, Material financial obligation, Reg FD disclosure, Other events, Exhibits
SEC2/13/2026material
8-K — Reg FD disclosure, Other events, Exhibits
SEC2/11/2026material
8-K — Other events, Exhibits
SEC2/10/2026material
8-K — Results of operations, Reg FD disclosure, Exhibits
SEC2/4/2026material
10-Q filing
SEC2/4/2026
8-K — Executive/director change, Reg FD disclosure, Exhibits
SEC1/22/2026material
8-K — Material agreement, Material financial obligation, Exhibits
SEC1/16/2026material

2025

8-K — Reg FD disclosure, Other events, Exhibits
SEC12/15/2025material
10-K filing
SEC11/25/2025
8-K — Results of operations, Reg FD disclosure, Exhibits
SEC11/5/2025material
8-K — Material agreement, Exhibits
SEC9/9/2025material
8-K — Other events, Exhibits
SEC9/3/2025material

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.